Trial Outcomes & Findings for Using Partners to Enhance Long-Term Weight Loss (NCT NCT03801174)
NCT ID: NCT03801174
Last Updated: 2024-06-06
Results Overview
Measured on a calibrated, digital scale to the nearest 0.1 kg, assessed every 6 months with 24 months as primary endpoint
COMPLETED
NA
346 participants
24 months
2024-06-06
Participant Flow
Enrollment numbers reflect only patients, not dyads, as this is how the study analysis was powered.
Enrollment numbers reflect only patients, not dyads. Partners were not assessed and therefore are not their own arm. Partners were not considered as enrolled, and are not included in the reported enrollment number. Partners did not have Baseline, pre-specified Primary and/or Secondary Outcome Measure, and Adverse Event data collected.
Participant milestones
| Measure |
Partner-assisted Intervention: Patient
Patients and partners will receive intervention
Partner-assisted intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
Patient-only Intervention
Patients will receive intervention
Patient-only intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
|---|---|---|
|
Overall Study
STARTED
|
115
|
116
|
|
Overall Study
COMPLETED
|
63
|
80
|
|
Overall Study
NOT COMPLETED
|
52
|
36
|
Reasons for withdrawal
| Measure |
Partner-assisted Intervention: Patient
Patients and partners will receive intervention
Partner-assisted intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
Patient-only Intervention
Patients will receive intervention
Patient-only intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
14
|
15
|
|
Overall Study
Death
|
1
|
0
|
|
Overall Study
Pregnancy
|
2
|
2
|
|
Overall Study
Lost to Follow-up
|
19
|
10
|
|
Overall Study
Other
|
4
|
3
|
|
Overall Study
Lack of Efficacy
|
4
|
0
|
|
Overall Study
Unwilling to complete activities
|
5
|
6
|
|
Overall Study
Moved out of area
|
3
|
0
|
Baseline Characteristics
Using Partners to Enhance Long-Term Weight Loss
Baseline characteristics by cohort
| Measure |
Partner-assisted Intervention: Patient
n=115 Participants
Patients and partners will receive intervention
Partner-assisted intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
Patient-only Intervention
n=116 Participants
Patients will receive intervention
Patient-only intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
Total
n=231 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
Participant
|
47.3 years
STANDARD_DEVIATION 11.31 • n=5 Participants
|
47.24 years
STANDARD_DEVIATION 11.76 • n=7 Participants
|
47.27 years
STANDARD_DEVIATION 11.51 • n=5 Participants
|
|
Sex/Gender, Customized
Identify as Female
|
76 participants
n=5 Participants
|
79 participants
n=7 Participants
|
155 participants
n=5 Participants
|
|
Sex/Gender, Customized
Identify as Male
|
37 participants
n=5 Participants
|
37 participants
n=7 Participants
|
74 participants
n=5 Participants
|
|
Sex/Gender, Customized
Genderqueer
|
1 participants
n=5 Participants
|
0 participants
n=7 Participants
|
1 participants
n=5 Participants
|
|
Sex/Gender, Customized
Multi-gender
|
1 participants
n=5 Participants
|
0 participants
n=7 Participants
|
1 participants
n=5 Participants
|
|
Sex/Gender, Customized
Birth sex - Female
|
78 participants
n=5 Participants
|
79 participants
n=7 Participants
|
157 participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
6 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
10 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
108 Participants
n=5 Participants
|
112 Participants
n=7 Participants
|
220 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
2 Participants
n=5 Participants
|
1 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Asian
|
6 Participants
n=5 Participants
|
6 Participants
n=7 Participants
|
12 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Black or African American
|
4 Participants
n=5 Participants
|
4 Participants
n=7 Participants
|
8 Participants
n=5 Participants
|
|
Race (NIH/OMB)
White
|
97 Participants
n=5 Participants
|
101 Participants
n=7 Participants
|
198 Participants
n=5 Participants
|
|
Race (NIH/OMB)
More than one race
|
5 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
7 Participants
n=5 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
3 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
115 participants
n=5 Participants
|
116 participants
n=7 Participants
|
231 participants
n=5 Participants
|
|
Body weight
|
106.20 kilograms
STANDARD_DEVIATION 19.03 • n=5 Participants
|
106.90 kilograms
STANDARD_DEVIATION 19.84 • n=7 Participants
|
106.55 kilograms
STANDARD_DEVIATION 19.41 • n=5 Participants
|
|
Daily caloric intake
|
2182.66 kcal/day
STANDARD_DEVIATION 730.00 • n=5 Participants
|
2103.10 kcal/day
STANDARD_DEVIATION 737.88 • n=7 Participants
|
2142.88 kcal/day
STANDARD_DEVIATION 733.43 • n=5 Participants
|
|
Steps per day
|
8023.37 steps/day
STANDARD_DEVIATION 3412.32 • n=5 Participants
|
8203.70 steps/day
STANDARD_DEVIATION 3622.56 • n=7 Participants
|
8114.40 steps/day
STANDARD_DEVIATION 3512.68 • n=5 Participants
|
PRIMARY outcome
Timeframe: 24 monthsMeasured on a calibrated, digital scale to the nearest 0.1 kg, assessed every 6 months with 24 months as primary endpoint
Outcome measures
| Measure |
Partner-assisted Intervention
n=115 Participants
Patients and partners will receive intervention
Partner-assisted intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
Patient-only Intervention
n=116 Participants
Patients will receive intervention
Patient-only intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
|---|---|---|
|
Body Weight (kg)
|
104.46 kilograms
Interval 101.73 to 107.18
|
104.23 kilograms
Interval 101.54 to 106.92
|
SECONDARY outcome
Timeframe: 24 monthsaverage estimated daily intake from ASA24 Dietary Assessment Tool, assessed every 6 months with 24 months as primary endpoint
Outcome measures
| Measure |
Partner-assisted Intervention
n=115 Participants
Patients and partners will receive intervention
Partner-assisted intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
Patient-only Intervention
n=116 Participants
Patients will receive intervention
Patient-only intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
|---|---|---|
|
Caloric Intake (kcal)
|
1835 KCALs/day
Interval 1689.0 to 1980.0
|
1885 KCALs/day
Interval 1746.0 to 2024.0
|
SECONDARY outcome
Timeframe: 24 monthsaverage daily steps over past 7 days from Fitbit, assessed every 6 months with 24 months as primary endpoint
Outcome measures
| Measure |
Partner-assisted Intervention
n=115 Participants
Patients and partners will receive intervention
Partner-assisted intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
Patient-only Intervention
n=116 Participants
Patients will receive intervention
Patient-only intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
|---|---|---|
|
Physical Activity
|
7400 steps/day
Interval 6615.0 to 8186.0
|
8206 steps/day
Interval 7475.0 to 8936.0
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 3 monthsScore based on 12-item Unidimensional Relationship Closeness Scale (1-7, strongly disagree to strongly agree) and single-item Inclusion of Other in Self scale (7 Venn diagrams)
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 3 months5 items assessed on 11-point scale ranging from 0 (not at all effective) to 10 (very effective)
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 3 months5 items assessed on 11-point scale ranging from 0 (not at all confident) to 10 (very confident)
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 3 months9 items assessed on 5-point scale (never, rarely, sometimes, often, almost always)
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 3 months5 items assessed on 5-point frequency scale (never, sometimes, frequently, often, very often)
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 3 monthsScore based on 12-item Unidimensional Relationship Closeness Scale (1-7, strongly disagree to strongly agree) and single-item Inclusion of Other in Self scale (7 Venn diagrams)
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 3 months5 items assessed on 11-point scale ranging from 0 (not at all effective) to 10 (very effective)
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 3 months5 items assessed on 11-point scale ranging from 0 (not at all confident) to 10 (very confident)
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 3 months9 items assessed on 5-point scale (never, rarely, sometimes, often, almost always)
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: 3 months5 items assessed on 5-point frequency scale (never, sometimes, frequently, often, very often)
Outcome measures
Outcome data not reported
Adverse Events
Partner-assisted Intervention
Patient-only Intervention
Serious adverse events
| Measure |
Partner-assisted Intervention
n=115 participants at risk
Patients and partners will receive intervention
Partner-assisted intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
Patient-only Intervention
n=116 participants at risk
Patients will receive intervention
Patient-only intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
|---|---|---|
|
Cardiac disorders
Atrial fibrillation
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Cardiac disorders
Cardiac ablation
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Cardiac disorders
Death
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Gastrointestinal disorders
Ulcerative colitis
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
General disorders
Adverse medication interaction
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Covid-19
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Surgical and medical procedures
Hip replacement
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
Other adverse events
| Measure |
Partner-assisted Intervention
n=115 participants at risk
Patients and partners will receive intervention
Partner-assisted intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Partners will attend some patient group sessions and be informed of patients' goals and relapse plans. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
Patient-only Intervention
n=116 participants at risk
Patients will receive intervention
Patient-only intervention: All patients will receive group-based weight loss program for 6 months featuring a calorie-restricted diet and physical activity. Then, all patients will receive a weight loss maintenance intervention for 12 months that involves maintenance-specific content, transitions to individual telephone calls, and decreases frequency of contact. Intervention will be withdrawn for the last 6 months to examine sustainability of effects.
|
|---|---|---|
|
Blood and lymphatic system disorders
Anemic
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Cardiac disorders
Cardiac arrhythmia
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Cardiac disorders
Tachycardia
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Ear and labyrinth disorders
Ear infection
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Endocrine disorders
Endocrinologist prescribed diet change
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Endocrine disorders
Hyperthyroidism
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Endocrine disorders
Nonclassical congenital adrenal hyperplasia
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Gastrointestinal disorders
Burning mouth syndrome
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Gastrointestinal disorders
Diarrhea
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Gastrointestinal disorders
Gastritis
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Gastrointestinal disorders
Heartburn
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
1.7%
2/116 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
|
Gastrointestinal disorders
Hernia
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Gastrointestinal disorders
Irritable bowel syndrome
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Gastrointestinal disorders
Pravovirus
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Gastrointestinal disorders
Stomach ache
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
1.7%
2/116 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
|
Gastrointestinal disorders
Ulcerative colitis
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
General disorders
Common cold
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
General disorders
Fatigue
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
General disorders
Fever and chills
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
General disorders
Mouth pain
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
General disorders
Swollen feet
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Hepatobiliary disorders
Liver disease
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Immune system disorders
Allergic reaction
|
1.7%
2/115 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Bell's palsy
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Blood infection
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Bronchitis
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
1.7%
2/116 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Common cold
|
6.1%
7/115 • Number of events 8 • 24 months
Partners were not assessed for adverse events.
|
6.9%
8/116 • Number of events 12 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Ear infection
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Eye infection
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Flu
|
1.7%
2/115 • Number of events 3 • 24 months
Partners were not assessed for adverse events.
|
6.0%
7/116 • Number of events 8 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Food poisoning
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Gastroenteritis
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Kidney infection
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Leg infection
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Post-surgical infection
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Respiratory infection
|
1.7%
2/115 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Sinus infection
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
1.7%
2/116 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Strep throat
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Tooth abscess
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Urinary tract infection
|
0.87%
1/115 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Infections and infestations
Vomiting
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Injury, poisoning and procedural complications
Broken ankle
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Injury, poisoning and procedural complications
Broken arm
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Injury, poisoning and procedural complications
Broken ribs
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Injury, poisoning and procedural complications
Foot injury
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Injury, poisoning and procedural complications
Fractured sacrum
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Investigations
Hypercholesterolemia
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Investigations
Thrombocytopenia
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Metabolism and nutrition disorders
Gluten intolerant
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Metabolism and nutrition disorders
Pre-diabetes diagnosis
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Metabolism and nutrition disorders
Type II diabetes diagnosis
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
ACL tear
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
1.7%
2/115 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Fibromyalgia
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Foot pain
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Frozen shoulder
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Heel spurs
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Hip bursitis
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Hip pain
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Knee arthritis
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Knee injury
|
3.5%
4/115 • Number of events 4 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Knee pain
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Leg injury
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Meniscus tear
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Plantar fasciitis
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Rotator cuff surgery
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Shoulder calcium deposits
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Shoulder fibrosis
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Shoulder injury
|
2.6%
3/115 • Number of events 3 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Shoulder pain
|
0.87%
1/115 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Sprained ankle
|
1.7%
2/115 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
1.7%
2/116 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Torn hamstring
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Musculoskeletal and connective tissue disorders
Torn labrum
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cyst removed
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial polyp
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Nervous system disorders
Dizzy spells
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Nervous system disorders
Headache
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
1.7%
2/116 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
|
Nervous system disorders
Leg nerve pain
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Nervous system disorders
Neuropathy
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Psychiatric disorders
Binge eating disorder
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
|
Psychiatric disorders
Depression
|
2.6%
3/115 • Number of events 3 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Psychiatric disorders
Depression and anxiety
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
1.7%
2/116 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
|
Psychiatric disorders
Depression medication change
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Psychiatric disorders
Obsessive compulsive disorder diagnosis
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Psychiatric disorders
Sleep issues
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
1.7%
2/116 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
|
Renal and urinary disorders
Bladder cancer
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Renal and urinary disorders
Kidney stone
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Renal and urinary disorders
Urinary tract burning
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Reproductive system and breast disorders
Amenorrhea
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Reproductive system and breast disorders
PCOS diagnosis
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Reproductive system and breast disorders
Prostate surgery
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Reproductive system and breast disorders
Uterine pain
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Reproductive system and breast disorders
Vaginal prolapse
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Covid-19
|
7.8%
9/115 • Number of events 9 • 24 months
Partners were not assessed for adverse events.
|
3.4%
4/116 • Number of events 4 • 24 months
Partners were not assessed for adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Heavy breathing
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Long Covid-19 symptoms
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Shortness of breath
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Sleep apnea
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
1.7%
2/116 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
|
Respiratory, thoracic and mediastinal disorders
Sore throat
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Skin and subcutaneous tissue disorders
Poison ivy
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
|
Skin and subcutaneous tissue disorders
Tick bite
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Surgical and medical procedures
Appendix removal
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Surgical and medical procedures
Back surgery
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Surgical and medical procedures
Breast biopsy
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Surgical and medical procedures
Cataract surgery
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Surgical and medical procedures
Dental crown procedure
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Surgical and medical procedures
Gall bladder removal
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
1.7%
2/116 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
|
Surgical and medical procedures
Knee replacement
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Surgical and medical procedures
Knee surgery
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
1.7%
2/116 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
|
Surgical and medical procedures
Meniscus tear
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Surgical and medical procedures
Root canal
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Surgical and medical procedures
Toe surgery
|
0.87%
1/115 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
0.00%
0/116 • 24 months
Partners were not assessed for adverse events.
|
|
Surgical and medical procedures
Tooth extraction
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
|
Vascular disorders
Hypertension
|
1.7%
2/115 • Number of events 2 • 24 months
Partners were not assessed for adverse events.
|
3.4%
4/116 • Number of events 4 • 24 months
Partners were not assessed for adverse events.
|
|
Vascular disorders
Varicose vein surgery
|
0.00%
0/115 • 24 months
Partners were not assessed for adverse events.
|
0.86%
1/116 • Number of events 1 • 24 months
Partners were not assessed for adverse events.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place